Sign Out
Known hypersensitivity to the active substances or to any of the excipients.
Severe hepatic impairment.
Narrow-angle glaucoma.
Pheochromocytoma.
Co-administration of a non-selective monoamine oxidase (MAO-A and MAO-B) inhibitors (eg, phenelzine, tranylcypromine).
Co-administration of a selective MAO-A and MAO-B inhibitor (see Other Antiparkinsonian Medicinal Products under Interactions). These inhibitors must be discontinued at least 2 weeks prior to initiating therapy with Stalevo.
A history of neuroleptic malignant syndrome (NMS) and/or nontraumatic rhabdomyolysis.
Lanjutkan dengan Google